Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘miRNA’

One way to potentially improve long term cancer statistics is earlier detection, and in high risk patients, appropriate initiation of earlier treatment, since it is well known that the survival in stage II or III breast cancer is noticeably better than that for stage IV metastatic disease.

A critical question then, is how do we improve earlier detection?

There are a number of ways to achieve this:

  1. Imaging techniques
  2. Prognostication
  3. Diagnostics
  4. Biomarkers

Following this morning’s blog post, I’ve been deluged with emails wanting to know more about the basics of miRNA and it’s role in cancer.  It’s a very complex topic, as Walter Jessen, a cancer researcher pointed out on Twitter in a discussion with Angela Alexander, a Ph.D student at MD Anderson and myself about miRNA:

“Complicated stuff, esp when expression of mirs doesn’t jive with expression of genes that reg them or that they reg.”

Where reg is ‘regulate’ since Twitter only allows 140 chars or less for communicating ideas between people 🙂  Still, this was exactly the problem I was experiencing when researching the topic recently.

error: Content is protected !!